Novo Nordisk launches Wegovy in UAE - Finance news and analysis from Global Banking & Finance Review
Finance

Novo Nordisk launches Wegovy in UAE 

Published by Global Banking & Finance Review

Posted on June 3, 2026

1 min read

· Last updated: June 3, 2026

Add as preferred source on Google

Novo Nordisk Introduces Wegovy Weight-Loss Drug to UAE Market

Novo Nordisk Launches Wegovy in the United Arab Emirates

Company Announcement

STOCKHOLM, June 3 (Reuters) - Novo Nordisk is launching its weight-loss drug Wegovy in the United Arab Emirates, it said in a statement on Wednesday.

Reporting and Editorial Credits

(Reporting by Anna Ringstrom, editing by Terje Solsvik)

Key Takeaways

  • The UAE has approved the oral Wegovy pill, positioning the country as a regional leader in offering innovative obesity treatments alongside the previously approved injectable form (gulfnews.com).
  • Wegovy (semaglutide) is a GLP‑1 receptor agonist with demonstrated efficacy in long‑term weight loss, maintenance, and reduction of cardiovascular risk when paired with diet and exercise (gulfnews.com).
  • This launch supports Novo Nordisk’s global rollout strategy for its oral weight‑loss product outside the U.S., where it already boosted first‑quarter performance and drove raised full‑year guidance (marketscreener.com)

References

Frequently Asked Questions

What product has Novo Nordisk launched in the UAE?
Novo Nordisk has launched its weight-loss drug Wegovy in the United Arab Emirates.
Who announced the launch of Wegovy in the UAE?
Novo Nordisk announced the launch in an official statement.
When was the launch of Wegovy in the United Arab Emirates announced?
The announcement was made on June 3.
Who reported the news about Wegovy's launch in the UAE?
The news was reported by Anna Ringstrom and edited by Terje Solsvik.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category